ACAD חוב כולל להון ACADIA Pharmaceuticals Inc.
The financial quote visualization for ACADIA Pharmaceuticals (ACAD) on the GURU.Markets platform demonstrates a total debt-to-equity ratio of 0.06. ACADIA Pharmaceuticals (ACAD) is mitigating risks through partnerships with neurobiological centers to expedite therapy launches. The brand's high authority in treating CNS disorders ensures physician loyalty. Stable drug sales and internal development cycles render the business profitability independent of external economic fluctuations.
פילוחים אנליטיים ודוחות נתונים של חברת ACADIA Corp (ACAD)
Fundamental issuer selection requires a rigorous analysis of debt load to eliminate default risk during market volatility. This ratio measures the proportion of borrowed funds relative to equity, allowing for an assessment of the financial stability of ACADIA Pharmaceuticals (ACAD) as it scales Parkinson's disease therapy and expands into the Rett syndrome segment via the current debt-to-equity ratio.